Neuroendocrine Tumors
Conditions
Brief summary
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
Interventions
20mg/30mg Q4W
Sponsors
Qilu Hospital of Shandong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Sign an informed consent form and voluntarily participate in this study; 2. Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study; 3. Age ≥ 18 years old; 4. Treatment with octreotide microspheres.
Exclusion criteria
1. Confirmed pregnant or lactating women; 2. Participating in any research with intervention measures outside of routine clinical practice; 3. Other situations unsuitable for inclusion in the study determined by the researcher.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Emergent Adverse Events | up to 46 months | Treatment emergent adverse events were recorded according to Common Terminology Criteria for Adverse Events (version 5.0) of the National Cancer Institute that participants received at least one dose of protocol treatment. |
Countries
China
Contacts
Primary ContactJian Wang, Dr.
Outcome results
None listed